Protected PCI Scientific Overview

Largest FDA Study of High-Risk PCI Patients Shows Improved Outcomes with Impella® Heart Pumps

Jeffrey J. Popma, MD, presents the latest data from the PROTECT series clinical study...

New PROTECT III Data Demonstrates Impella® Reduces MACCE at Primary Endpoint

New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery

New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients...

For Best Outcomes in AMI Cardiogenic Shock, Place Impella 2.5® or Impella CP® Pre-PCI

A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardio...

Impella RP® Heart Pump Patient Selection Criteria Checklist

Use this FDA-approved checklist to guide treatment decisions and determine if the Impella RP is right for your patients....

Dr. O’Neill’s IQ Data and AMICS Presentation from TCT 2018

Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) suppor...

Renal Effects of Impella Support During Protected PCI

Dr. Michael P. Flaherty's TCT 2018 presentation on Renal Effects of Impella support during Protected PCI....

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...

Dr. O’Neill’s Presentation from TCT 2017

IMPRESS in Severe Shock Trial: Looking Closer at the Data

Dr. O’Neill’s Presentation from ACC 2017

Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery

The Science of Hemodynamic Support